Anti-PPAR gamma antibody (ab59256)
- Product nameAnti-PPAR gamma antibodySee all PPAR gamma primary antibodies ...
- DescriptionRabbit polyclonal to PPAR gamma
- Specificityab59256 detects endogenous levels of total PPAR gamma protein.
- Tested applicationsICC/IF, ELISA, IHC-P more details
- Species reactivityReacts with: Mouse, Human
Synthetic non-phosphopeptide derived from human PPAR gamma around the phosphorylation site of serine 112 (P-A-SP-P-P).
- Positive controlHuman placenta tissue.
- Storage instructionsStore at -20°C. Stable for 12 months at -20°C
- Storage bufferPreservative: 0.02% Sodium Azide
Constituents: 50% Glycerol, PBS (without Mg2+ and Ca2+), 150mM Sodium chloride, pH 7.4
- Concentration information loading...
- PurityImmunogen affinity purified
- Purification notesab59256 was affinity purified from rabbit antiserum by affinity chromatography using epitope specific immunogen.
- Clonality Polyclonal
- Pathways and Processes
- Metabolic signaling pathways
- Lipid and lipoprotein metabolism
- Fatty acids
Our Abpromise guarantee covers the use of ab59256 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|ICC/IF||ICC/IF: Use a concentration of 5 µg/ml.|
|IHC-P||IHC-P: Use at an assay dependent dilution.|
- FunctionReceptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the receptor binds to a promoter element in the gene for acyl-CoA oxidase and activates its transcription. It therefore controls the peroxisomal beta-oxidation pathway of fatty acids. Key regulator of adipocyte differentiation and glucose homeostasis.
- Tissue specificityHighest expression in adipose tissue. Lower in skeletal muscle, spleen, heart and liver. Also detectable in placenta, lung and ovary.
- Involvement in diseaseNote=Defects in PPARG can lead to type 2 insulin-resistant diabetes and hyptertension. PPARG mutations may be associated with colon cancer.
Defects in PPARG may be associated with susceptibility to obesity (OBESITY) [MIM:601665]. It is a condition characterized by an increase of body weight beyond the limitation of skeletal and physical requirements, as the result of excessive accumulation of body fat.
Defects in PPARG are the cause of familial partial lipodystrophy type 3 (FPLD3) [MIM:604367]. Familial partial lipodystrophies (FPLD) are a heterogeneous group of genetic disorders characterized by marked loss of subcutaneous (sc) fat from the extremities. Affected individuals show an increased preponderance of insulin resistance, diabetes mellitus and dyslipidemia.
Genetic variations in PPARG can be associated with susceptibility to glioma type 1 (GLM1) [MIM:137800]. Gliomas are central nervous system neoplasms derived from glial cells and comprise astrocytomas, glioblastoma multiforme, oligodendrogliomas, and ependymomas. Note=Polymorphic PPARG alleles have been found to be significantly over-represented among a cohort of American patients with sporadic glioblastoma multiforme suggesting a possible contribution to disease susceptibility.
- Sequence similaritiesBelongs to the nuclear hormone receptor family. NR1 subfamily.
Contains 1 nuclear receptor DNA-binding domain.
- Cellular localizationNucleus.
- CIMT1 antibodyGLM1 antibodyHUMPPARG antibody
- NR1C3 antibodyNuclear receptor subfamily 1 group C member 3 antibodyOTTHUMP00000185032 antibodyOTTHUMP00000185036 antibodyPAX8/PPARG Fusion Gene antibodyPeroxisome proliferator activated nuclear receptor gamma variant 1 antibodyPeroxisome proliferator activated receptor gamma 1 antibodyPeroxisome Proliferator Activated Receptor gamma antibodyPeroxisome proliferator-activated receptor gamma antibodyPPAR gamma antibodyPPAR-gamma antibodyPPARG antibodyPPARG_HUMAN antibodyPPARG1 antibodyPPARG2 antibodyPPARG3 antibody
Anti-PPAR gamma antibody images
ab59256, at 1/50 dilution, staining PPAR gamma in paraffin embedded human placenta tissue by Immunohistochemistry in the absence or presence of the immunising peptide.
ICC/IF image of ab59256 stained MCF7 cells. The cells were 4% PFA fixed (10 min) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab59256, 5µg/ml) overnight at +4°C. The secondary antibody (green) was Alexa Fluor® 488 goat anti-rabbit IgG (H+L) used at a 1/1000 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM.
References for Anti-PPAR gamma antibody (ab59256)
This product has been referenced in:
- Ortega HH et al. Developmental programming: effect of prenatal steroid excess on intraovarian components of insulin signaling pathway and related proteins in sheep. Biol Reprod 82:1065-75 (2010). Read more (PubMed: 20147730) »
- Krieger-Hinck N et al. The effect of the PPAR-gamma agonist rosiglitazone on neuroblastoma SK-N-SH cells in a metastatic xenograft mouse model. Oncol Res 18:387-93 (2010). Read more (PubMed: 20441053) »